Medigen Biotechnology (3176) — Capital Reinvestment Ratio
Medigen Biotechnology (3176) has a Capital Reinvestment Ratio of 0.06x as of December 2024, meaning it reinvests 0% of its operating cash flow (NT$156.75 Million) in capital expenditures (NT$9.09 Million). See Medigen Biotechnology balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Medigen Biotechnology Capital Reinvestment Ratio (2003–2024)
This chart tracks Medigen Biotechnology's Capital Reinvestment Ratio across 5 annual periods. Check Medigen Biotechnology cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Medigen Biotechnology (2003–2024)
Year-by-year Capital Reinvestment Ratio for Medigen Biotechnology from 2003 to 2024. For live market cap and broader valuation context, see Medigen Biotechnology (3176) total market value.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.55x | NT$37.92 Million | NT$58.68 Million | ▲ +453.9% |
| 2021 | 0.28x | NT$517.45 Million | NT$144.55 Million | ▼ -84.1% |
| 2015 | 1.75x | NT$294.18 Million | NT$515.25 Million | ▲ +4303.1% |
| 2005 | 0.04x | NT$80.72 Million | NT$3.21 Million | ▲ +347.7% |
| 2003 | 0.01x | NT$445.46 Million | NT$3.96 Million | — |